Alvotech deal could heighten biosimilar pressure on Humira

  • Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access to their biosimilar version of AbbVie’s blockbuster drug Humira, Alvotech said Friday. An Alvotech spokesperson declined to provide specifics.
  • The deal comes seven weeks after the Food and Drug Administration approved Alvotech’s biosimilar, Simlandi, which the agency previously rejected multiple times. For patients to receive treatment, Alvotech and Teva must first cut deals with drug wholesalers, pharmacies and insurers that negotiate prices before agreeing to cover the therapy.
  • CVS Health, whose pharmacy benefit manager is the country’s largest by prescription claims, removed Humira from its national formulary on April 1. Wall Street analysts have already reported substantial declines in Humira prescriptions over the last few weeks, when compared to the same period in 2023.

Alvotech’s stumbles in winning approval of Simlandi put the company at a significant…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks